関連ニュース

Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve s

Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in service

Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million, roughly flat from $39.8 million a year earlier, while announcing an immediate leadership transition